ALEX BADAMCHI-ZADEH

Alex Badamchi-Zadeh is a Senior Associate at SV Health Investors, a prominent venture capital firm dedicated to advancing healthcare innovation. Based in London, Alex is an integral part of the investment team, specializing in early-stage opportunities within the dynamic fields of biotechnology and digital health. His expertise lies in identifying groundbreaking scientific and technological advancements that have the potential to significantly impact patient care and outcomes.

At SV Health Investors, Alex contributes to the full investment lifecycle, from initial sourcing and comprehensive due diligence to deal structuring and ongoing portfolio support. His focus areas align with SV Health Investors' broader mission to back companies developing novel therapeutics, diagnostics, and digital solutions that address unmet medical needs. He is particularly keen on ventures that leverage cutting-edge science and technology to create transformative healthcare solutions.

Alex's career trajectory at SV Health Investors demonstrates a deep commitment to healthcare venture capital. He joined the firm as an Analyst in July 2018, progressing to Associate in July 2020, and then to Senior Associate in July 2022. This progression highlights his growing influence and expertise within the firm and the broader healthcare investment landscape. His background is firmly rooted in bioscience, holding an MPhil in Bioscience Enterprise from the University of Cambridge and a BSc in Biochemistry from Imperial College London. This strong academic foundation provides him with a critical understanding of the scientific and commercial complexities inherent in healthcare innovation.

Throughout his tenure, Alex has been actively involved with several portfolio companies, often serving as a Board Observer. His notable involvements include Exogene, Purespring Therapeutics, NodThera, Artios Pharma, Pulmocide, Mestag Therapeutics, and Alchemab. These roles underscore his hands-on approach to supporting companies from their early stages through significant growth milestones, providing strategic guidance and leveraging SV Health Investors' extensive network and resources. His contributions help these pioneering companies navigate the challenges of drug development, market entry, and scaling their operations, ultimately bringing new solutions to patients worldwide.

Alex Badamchi-Zadeh's dedication to fostering innovation in biotechnology and digital health makes him a key figure in the European healthcare venture capital ecosystem. His work at SV Health Investors continues to drive investment into companies poised to redefine the future of medicine.